CMAJ • March 29, 2005; 172 (7). doi:10.1503/cmaj.045019.
© 2005 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v172,p1164)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soon, J. A.
Right arrow Articles by Fielding, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soon, J. A.
Right arrow Articles by Fielding, D. W.
Related Collections
Right arrow Other women's health
Right arrow Other obstetrics & gynecology
Right arrow Family planning, contraception

Effects of making emergency contraception available without a physician's prescription: a population-based study

Judith A. Soon, Marc Levine, Brenda L. Osmond, Mary H.H. Ensom and David W. Fielding

From the School of Pharmacy, University of Washington, Seattle, Wash. (Soon); the Faculty of Pharmaceutical Sciences, University of British Columbia (Soon, Levine, Osmond, Ensom, Fielding); the Children's & Women's Health Centre of British Columbia (Levine); the College of Pharmacists of British Columbia (Osmond); and the Children's & Women's Health Centre of British Columbia (Ensom), Vancouver, BC



View larger version (34K):

[in a new window]
  		Fig. 1: Algorithm used to exclude potential non-EC prescriptions for Ovral. Data for 2001 are presented here and were used to validate the algorithm. *ICD-10 codes for which Ovral is prescribed for non-EC indications: 617 (endometriosis), 625 (pain and other symptoms associated with female genital organs), 626 (disorders of menstruation and other abnormal uterine bleeding) and 639 (complication following abortion or ectopic or molar pregnancy). {dagger}These quantities are commonly associated with EC use: 4 represents 1 treatment, 5–6 include additional pills in case of vomiting, 8 represents 2 treatments and 21 for immediate and future use.

 


View larger version (17K):

[in a new window]
  		Fig. 2: Comparison of EC prescriptions for the Yuzpe regimen (Ovral or Preven) and levonorgestrel (Plan B) by type of provider in 2001–2002 in British Columbia.

 

View this table:

[in a new window]
  		Table 1.

 

View this table:

[in a new window]
  		Table 2.

 


View larger version (14K):

[in a new window]
  		Fig. 3: Predicted probability of pregnancy (diamonds) and percent of EC use (bars) by day in menstrual cycle.